Organon & Co. (NYSE:OGN) Stock Now Rated "Reduce" by Wall Street Brokerages

Key Points

• Wall Street’s consensus rating is “Reduce”: Two analysts rate Organon & Co. a sell and five recommend holding the stock. The average 12-month price target is $11.40, below its recent $13.78 price, while Weiss Ratings separately upgraded its assessment to “hold.”
• Organon shares are trading near their 52-week high of $13.83, with a market capitalization of $3.62 billion and a high debt-to-equity ratio of 8.43.
• The company pays a quarterly dividend of $0.02, equivalent to $0.08 annually and a modest 0.6% yield. Institutional investors own approximately 77.43% of the outstanding shares.

Shares of Organon & Co. (NYSE:OGN - Get Free Report) have been assigned an average rating of "Reduce" from the seven brokerages that are presently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and five have assigned a hold rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.40.

Separately, Weiss Ratings raised Organon & Co. from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday.

Organon & Co. Stock Performance

NYSE:OGN traded up $0.01 during trading hours on Tuesday, hitting $13.78. 702,842 shares of the company were exchanged, compared to its average volume of 5,195,578. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44. The company's 50 day moving average price is $13.71 and its 200-day moving average price is $12.59. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.83. The stock has a market capitalization of $3.62 billion, a price-to-earnings ratio of 17.89, a PEG ratio of 1.28 and a beta of 1.55.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 10th. Shareholders of record on Friday, August 14th were given a dividend of $0.02 per share. The ex-dividend date was Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.'s dividend payout ratio is currently 10.39%.

Institutional Trading of Organon & Co.

Several large investors have recently bought and sold shares of OGN. California State Teachers Retirement System grew its holdings in shares of Organon & Co. by 34.8% in the first quarter. California State Teachers Retirement System now owns 327,075 shares of the company's stock valued at $1,959,000 after purchasing an additional 84,497 shares during the period. WINTON GROUP Ltd acquired a new position in Organon & Co. during the second quarter worth $6,904,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Organon & Co. during the 2nd quarter valued at about $770,000. Sei Investments Co. boosted its stake in shares of Organon & Co. by 82.0% in the first quarter. Sei Investments Co. now owns 190,057 shares of the company's stock valued at $1,139,000 after purchasing an additional 85,657 shares during the period. Finally, Orographic Financial Advisors LLC purchased a new stake in shares of Organon & Co. during the first quarter worth $1,522,000. Hedge funds and other institutional investors own 77.43% of the company's stock.

About Organon & Co.

Organon & Co is a global healthcare company focused primarily on women's health, biosimilars and a portfolio of established medicines. The company develops, manufactures and commercializes prescription products designed to address a range of health needs, with an emphasis on expanding access to treatments in markets around the world.

Its women's health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines used in areas including fertility and reproductive health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.